Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.
- Published In:
- The Journal of clinical investigation, 95(1), 341-9 (1995)
- Authors:
- Vitiello, A, Ishioka, G, Grey, H M, Rose, R, Farness, P, LaFond, R, Yuan, L, Chisari, F V, Furze, J, Bartholomeuz, R
- Database ID:
- RPEP-00347
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00347APA
Vitiello, A; Ishioka, G; Grey, H M; Rose, R; Farness, P; LaFond, R; Yuan, L; Chisari, F V; Furze, J; Bartholomeuz, R. (1995). Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.. The Journal of clinical investigation, 95(1), 341-9.
MLA
Vitiello, A, et al. "Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans.." The Journal of clinical investigation, 1995.
RethinkPeptides
RethinkPeptides Research Database. "Development of a lipopeptide-based therapeutic vaccine to tr..." RPEP-00347. Retrieved from https://rethinkpeptides.com/research/vitiello-1995-development-of-a-lipopeptidebased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.